LOVD–DASH: A comprehensive LOVD database coupled with diagnosis and an at-risk assessment system for hemoglobinopathies

Li Zhang¹,²,³,* | Qianqian Zhang¹,²,³* | Yaohua Tang⁴ | Peikuan Cong⁵ |
Yuhua Ye¹,²,³ | Shiping Chen⁶ | Xinhua Zhang⁷ | Yan Chen⁸ | Baosheng Zhu⁹ |
Wangwei Cai¹⁰ | Shaoke Chen¹¹ | Ren Cai¹² | Xiaoling Guo¹³ | Chonglin Zhang¹⁴ |
Yuqiu Zhou¹⁵ | Jie Zou¹⁶ | Yanhui Liu¹⁷ | Biyan Chen¹⁸ | Shanhuo Yan¹⁹ |
Yajun Chen²⁰ | Yuehong Zhou²¹ | Hongmei Ding²² | Xiarong Li²³ | Dianyu Chen²⁴ |
Jianmei Zhong¹,²,³ | Xuan Shang¹,²,³ | Xuanzu Liu²³ | Ming Qi²⁴,²⁵ | Xiangmin Xu¹,²,³

¹Department of Medical Genetics, Southern Medical University, Guangzhou, Guangdong, China
²Guangdong Technology and Engineering Research Center for Molecular Diagnostics of Human Genetic Diseases, Guangzhou, Guangdong, China
³Guangdong Key Laboratory of Biological Chip, Guangzhou, Guangdong, China
⁴DIAN Diagnostics, Hangzhou, China
⁵Institute for Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, Zhejiang, China
⁶BGI Clinical Laboratories-Shenzhen, Shenzhen, Guangdong, China
⁷Department of Hematopathology, 303rd Hospital of the People's Liberation Army, Nanning, Guangxi, China
⁸Department of Pediatrics, Affiliated Hospital of Zunyi Medical University, Zunyi, China
⁹Genetic Diagnosis Center, First People’s Hospital of Yunnan Province, Kunming, Yunnan, China
¹⁰School of Basic Medicine, Hainan Medical University, Haikou, Hainan, China
¹¹Department of Pediatrics, Guangxi Zhuang Autonomous Region Women and Children Health Care Hospital, Nanning, Guangxi, China
¹²Department of Medical Genetics, Liuzhou Municipal Maternity and Child Healthcare Hospital, Liuzhou, Guangxi, China
¹³Department of Pediatrics, Maternity and Child Health Care Hospital of Foshan City, Foshan, Guangdong, China
¹⁴Department of Clinical Laboratory, Guilin Women and Children health care hospital, Guilin, Guangxi, China
¹⁵Department of Clinical Laboratory, Zuhai Municipal Maternity and Child Healthcare Hospital, Zuhai, Guangdong, China
¹⁶Department of Clinical Laboratory, Maternal and Child Health Hospital in Meizhou, Meizhou, Guangdong, China
¹⁷Department of Prenatal Diagnosis Center, Maternal and Child Health Hospital, Dongguan, Guangdong, China
¹⁸Department of Clinical Laboratory, Baise Women and Children Care Hospital, Baise, Guangxi, China
¹⁹Department of Clinical Laboratory, Qinzhou Maternal and Child Health Hospital, Qinzhou, Guangxi, China
²⁰Center For Prenatal Diagnosis Shaoquan, Shaoguan Municipal Maternity and Child Healthcare Hospital, Guangdong, China
²¹Department of Clinical Laboratory, The People's Hospital of Yunfu City, Yunfu, Guangdong, China
²²Department of Clinical Laboratory, Pingguo Women and Children Care Hospital, Baise, Guangxi, China
²³Beijing GeneDock Technology Company, Beijing, China
²⁴School of Basic Medical Sciences, Zhejiang University, Hangzhou, Zhejiang, China
²⁵Center for Genetic & Genomic Medicine, James Watson Institute of Genome Sciences, Zhejiang University Medical School 1st Affiliated Hospital, Hangzhou, Zhejiang, China

*Li Zhang and Qianqian Zhang contributed equally to this manuscript.
Hemoglobinopathies are the most common monogenic disorders worldwide. The major \( \beta \)-hemoglobinopathies, especially sickle cell disease and \( \beta \)-thalassemia are lethal hemoglobinopathies that have caused global health burdens due to their serious pathogenicity and high prevalence (Taher, Weatherall, & Cappellini, 2018; Weatherall, 2010). Previous efforts and programs for preventing hemoglobinopathies have proved to be effective in the Mediterranean populations, especially for \( \beta \)-thalassemia, showing a reduction from 1:250 live births to 1:1660 in 2009 (Cao & Kan, 2013). The birth rates of hemoglobinopathies, however, remain high. In China, approximately 12,900 newborns are estimated with hemoglobin disorders of various types each year, which in turn may cause a serious social burden (Shang et al., 2017; Xiong et al., 2010). The number of fetuses with hemoglobinopathies can be largely reduced if a robust system for clinicians is developed to master standard guidelines and to rapidly make correct clinical management choices for hemoglobinopathy patients or at-risk couples.

Previous observations involving hemoglobin switching have shown that elevated fetal hemoglobin expression ameliorates the severity of \( \beta \)-hemoglobinopathies (Vinjamur, Bauer, & Orkin, 2017). Thus, an accurate diagnosis of hemoglobinopathies calls for not only the proper genotyping of the disease-causing mutations in globin gene clusters, but also newly identified variants in modifier genes, such as KLF1, BCL11A, and GATA1, which are responsible for altered expression of \( \gamma \)-globin and also influence \( \beta \)-thalassemia severity (Bauer & Orkin, 2015; D. Liu et al., 2014; Thein et al., 2007). Substantial effort has been made to establish databases to record global mutation spectra causing and modifying hemoglobinopathies (Giardine et al., 2011; Kountouris et al., 2014). HbVar, built by Giardine et al. (Hardison et al., 2002) has thus far been an authoritative hemoglobinopathy database for both researchers and clinicians. We present herein a comprehensive variant database of hemoglobinopathies focusing on a Chinese population, recording the details of all reported variants through literature peer review-curation and existing databases. Moreover, unpublished data from our laboratory, including all the phenotype-genotype datasets derived from high-throughput sequencing data of 2,087 hemoglobinopathy patients and 20,222 general southern Chinese individuals, were also merged into the database (Shang et al., 2017). The addition of 34 novel functional variants from these genes has been detected using this high-throughput approach. All the variants are classified according to American College of Medical Genetics and Genomics (ACMG) recommendations with the use of specific standard terminology: "pathogenic", "likely pathogenic", "uncertain significance", "likely benign", and "benign". (Richards et al., 2015; Table S1). Details of all the variants are integrated into the Leiden Open Variation Database (LOVD), in which we included all reported variants focusing on a Chinese population by literature peer review-curation and existing databases, such as HbVar and IthaGenes. In addition, comprehensive mutation data generated by high-throughput sequencing of 2,087 hemoglobinopathy patients and 20,222 general individuals from southern China were also incorporated into the database. These sequencing data enabled us to observe disease-causing and modifier variants responsible for hemoglobinopathies in bulk. Currently, 371 unique variants have been recorded; 265 of 371 were described as disease-causing variants, whereas 106 were defined as modifier variants, including 34 functional variants identified by a quantitative trait association study of this high-throughput sequencing data. Due to the availability of a comprehensive phenotype-genotype data set, DASH has been established to automatically provide accurate suggestions on diagnosis and genetic counseling of hemoglobinopathies. LOVD-DASH will inspire us to deal with clinical genotyping and molecular screening for other Mendelian disorders.
Variation Database, which is available at http://www.genomed.zju.edu.cn/LOVD3 Genes.

An online auxiliary diagnosis and at-risk assessment system for inherited hemoglobinopathy (DASH) has also been established based on the following: (a) the integrity of the hemoglobinopathy mutation spectrum of a Chinese population; (b) the availability of a comprehensive phenotype-genotype data set corresponding to the 22,309 samples; and (c) the detailed information of variants according to the latest version of HbVar (Giardine et al., 2014). Aiming to accomplish the molecular screening and clinical genotyping of hemoglobinopathies in a Chinese population, DASH consists of three main workflows. DASH not only infers the thalassemia trait based on the input of the hematologic phenotype but also recognizes the uploaded copy number variants (CNVs) and single nucleotide variants (SNVs) data then interprets the data with a specific hemoglobinopathy annotation library. Both disease-causing and modifier variants will be evaluated for a combined analysis, which will ultimately lead to an overall hemoglobinopathy diagnosis. Furthermore, the system will conduct an at-risk assessment of known disease-causing mutations and reveal critical clinical information for potential offspring. A diagnostic and assessment report will be automatically presented which could provide accurate suggestions on diagnosis and genetic counseling of hemoglobinopathies. DASH is available at www.smuhemoglobinopathy.com.

In this study, we portrayed the most comprehensive mutation spectrum of hemoglobinopathies in the Chinese population. In addition, LOVD-DASH will make a contribution in research and clinical application and provide a new method for treatment and prevention of hemoglobinopathies in Chinese patients. With the LOVD database and DASH system, we are one step closer to complete molecular screening and accurate clinical genotyping of hemoglobinopathies.

2 | METHODS AND RESULTS

2.1 | LOVD database of hemoglobinopathy variants in a Chinese population

2.1.1 | Data collection and database content

The bulk of data on gene variants was derived from published data, including databases (HbVar: http://globin.cse.psu.edu/; IthaGenes: http://www.ithanet.eu/db/ithagenes), literature mining from PubMed (https://www.ncbi.nlm.nih.gov/pubmed), and Chinese core journals (http://xueshu.baidu.com/). The other source is unpublished data from our laboratory, including phenotype-genotype datasets derived from high-throughput sequencing data of 2,087 patients with hemoglobinopathy and 20,222 general previously mentioned southern Chinese individuals. The study was approved by the Medical Ethics Committee in accordance with the Declaration of Helsinki. All the clinical data of participants have been obtained and curated under agency ethical guidelines. Variations in globin genes (HBA1, MIM# 141800; HBA2, MIM# 141850; HBB, MIM# 141900; HBG1, MIM# 142200; HBG2, MIM# 142250; HBG, MIM# 142000) and nonglobin genes (BCL11A, MIM# 606557; KLF1, MIM# 600599; GATA1, MIM# 305371), as well as the intergenic region of HMIP (MIM# 142470), were categorized into disease-causing and modifiers, and would be accepted as keywords to perform literature mining on hemoglobinopathies. Currently, 371 unique variants have been recorded: 265 of the 371 unique variants were described as disease-causing variants, while 106 were defined as modifier variants (Table 1), including 34 functional variants identified by a quantitative trait association study of the high-throughput sequencing data in Plink (Figure S1; Table 2; Table S2). The inevitable bias caused by haplotype that the causative variant(s) among them cannot be judged simply by statistical approaches. For further research, the corresponding phenotypic information and genotypic data, including disease-causing and identified modifier variants in detail of 2,087 hemoglobinopathy cohort were displayed in http://www.genomed.zju.edu.cn/LOVD3/individuals.

2.1.2 | Database structure

Taking HBB as an example (Figure 1), all the datasets are classified and presented in different columns including genes, transcripts, variants, individuals, diseases, and so forth. For instance, "individuals" column contains the basic information, genotypes, and phenotypes of all individuals with variants in the HBB gene. Besides, the homepage of the variant database consists of the following three sections: (a) The general information section contains basic information about the HBB gene. The reference sequences of HBB can be obtained in this section. The entries of public variants can be found in the "total number of public variants reported" listing. Detailed information of variants, such as DNA change, protein change, variant type, location, and the information of patients are available for download; (b) The graphical display section offers diagrams to show summary information of all variants in the database; (c) The linkage section shows other authoritative resources, the including HUGO Gene Nomenclature Committee (https://www.genenames.org/), Entrez gene (http://www.ncbi.nlm.nih.gov/gene/), Online Mendelian Inheritance in Man (OMIM; http://www.omim.org), the Human Gene Mutation Database (HGMD; http://www.hgmd.cf.ac.uk/), Genecards (http://www.genecards.org/), and the Genetic Testing Registry (GTR; https://www.ncbi.nlm.nih.gov/gtr/).

2.1.3 | Data submission

The LOVD-China database is available for public submission. The submitter should register and sign in before submission. The literature or evidence which can support the clinical significance of the variants is required. Submitters should complete the variant data and corresponding phenotypic information in detail as much as possible. It is necessary that all variant data submitted should be named according to the nomenclature of the Human Genome Variation Society (HGVS; den Dunnen et al., 2016). The authors of this study are responsible for the manual curation of the database by checking each entry, adding new entries, and updating both existing variations and epidemiologic data. A more detailed introduction can be found in the documentation at http://www.genomed.zju.edu.cn/LOVD3/docs/.
Diagnosis and at-risk assessment system of hemoglobinopathies

2.2.1 | DASH structure

We integrated LOVD-China, the 22,309 phenotype-genotype individual data set, and HbVar data as a comprehensive hemoglobinopathy-specific annotation data set for DASH (Figure 2). DASH is freely accessible online where three main workflows can be chosen from the homepage, including the hemoglobinopathy inference module, the clinical genotyping module, and the at-risk assessment module.

2.2.2 | DASH for hemoglobinopathy inference

The hemoglobinopathy inference module provides a judgment algorithm according to the traditional routine strategy for thalassemia carrier screening (Traeger-Synodinos et al., 2015). Hematologic and biochemical tests and subsequent molecular genetic testing are required for identification (Danjou et al., 2015). Thus, both basic information and hematologic phenotype are required as the input. Basic information includes age, gender, and native places, while hematologic phenotype includes red blood cell indices (HGB, MCH, MCV, and Hb pattern [Hb A2 and Hb F]). A standard criterion was used for the judgment of the thalassemia trait (Figure S2). For example, a 5-year-old girl from Guangdong province of China had the following hematologic phenotype: MCH, 24 pg; MCV, 73 fL; Hb F, 3%; and Hb A2, 6% (http://www.genomed.zju.edu.cn/LOVD3/individuals/00001639) will be inferred as the β-thalassemia trait in the output report. In addition, clinical genotyping is highly recommended for this individual; however, individuals with "silent" forms of thalassemia are undetectable because such individuals have normal or borderline red cell indices and/or Hb A2 levels (Hallam et al., 2014). Moreover, it is important to note that iron deficiency alone or co-exist with the thalassemias can also cause microcytic hypochromic anemia, which could lead to misinterpretation. If an individual is found to be iron-deficient, it is recommended to repeat the hematologic screen once the individual is iron-replete (Traeger-Synodinos et al., 2015).

### TABLE 1

| Disease-causing variants | HBB | HBA1 | HBA2 | HBD | HBG1* | HBG2* |
|--------------------------|-----|------|------|-----|-------|-------|
| OMIM                     | 141900 | 141800 | 141850 | 142000 | 142200 | 142250 |
| Location                 | 11p15.4 | 16p13.3 | 16p13.3 | 11p15.4 | 11p15.4 | 11p15.4 |

| Pathogenicity            | Hb variant | 28 | 6 | 13 | 4 | 2 | 2 |
|                         | Thalassemia | 92 | 27 | 33 | 17 | 0 | 0 |
|                         | HPFHb       | 2 | 0 | 0 | 2 | 1 | 0 |
| Uncertain significance   |              | 2 | 11 | 8 | 2 | 8 | 5 |
| Total                    |              | 124 | 44 | 54 | 25 | 11 | 7 |

| Modifier variants        | KLF1c | BCL11A | HMIP | GATA1d | HBG1 | HBG2 |
|--------------------------|-------|--------|------|--------|------|------|
| OMIM                     | 600599 | 606557 | 142470 | 305371 | 142200 | 142250 |
| Location                 | 19p13.13 | 2p16.1 | 6q22.3–23.1 | Xp11.23 | 11p15.4 | 11p15.4 |
| Modification             |       |       |       |        |       |       |
| Elevated Hb F Level      | 18 | 3 | 17 | 0 | 5 | 4 |
| Decreased Hb F Level     | 0 | 9 | 3 | 0 | 4 | 7 |
| Uncertain significance   | 1 | 1 | 24 | 7 | 0 | 3 |
| Total                    | 19 | 13 | 44 | 7 | 9 | 14 |

Note: All the variants are classified according to ACMG recommendations. The pathogenicity was described as Hb variant, thalassemia, and hereditary persistence fetal hemoglobin (HPFH). "Hb variant" includes not only variants result in clinical significance, but all the reported abnormal hemoglobin variants. Modifier variants refer to all the collectible variants reported to be HbF-related or be significant in influencing the severity of hemoglobinopathies in the Chinese population. Variants in disease-causing genes without known pathogenicity were defined as the variants with "uncertain significance" (VUS). "Uncertain significance" in modifier variants, especially in HMIP region, refers to the variants reported to be HbF-related but with unclear modification.

Abbreviations: ACMG, American College of Medical Genetics and Genomics; LOVD, Leiden Open Variation Database; OMIM, Online Mendelian Inheritance in Man

aAppropriately, HBG1 and HBG2 genes can be classed as modifier genes. "Hb variant" in these genes referred to the variants which lead to abnormal fetal hemoglobin such as Hb F-Jiangsu (HBG1c:c.403G>A).

bHPFH involves only the deletion forms.

Although bulks of modifier variants have been detected in non-globin genes like BCL11A or HMIP region etc., functional variants within KLF1 have the most clinical significant influence on the severity of β-hemoglobinopathies in Chinese population.

cVariants in erythroid transcription factors GATA1 are reported to be related with HbF, HbA2, and severity of hemoglobinopathies.
2.2.3 | DASH for clinical genotyping

The clinical genotyping module consists of two sub-modules (hemoglobinopathy-specific annotation and genotype combinatorial analysis), which will be executed sequentially. Different format of hemoglobinopathy-related SNVs and CNVs list can be recognized as inputs, then annotated by the integrated comprehensive hemoglobinopathy-specific annotation data set. After annotation, disease-causing and modifier variants will be evaluated for a combined analysis, which ultimately leads to an overall hemoglobinopathy diagnosis, especially for \( \beta \)-thalassemia. For example, heterozygotes of the \( \beta \)-gene triplicates or quadruplicates will be reported as atypical thalassemia. For perfect use of this
module, the details of the input requirement are on the right side and output interpretation can be obtained in the Q&A from the homepage (http://www.smuhemoglobinopathy.com/question/#tab=1).

2.2.4 | DASH for at-risk assessment

At-risk assessment module has been established for couples, the variant list from individual and spouse are required. Format and examples of variants are provided in the right side of the module. For each individual, clinical genotyping will be performed first to get an overall hemoglobinopathy diagnosis, then combinatory analysis of variants of individual and spouse will report whether or not the offspring of this couple will be at-risk for hemoglobin disorders. The possible at-risk genotype and modifier variants of offspring will be reminded to assist the clinicians for comprehensive genetic counseling.

3 | DISCUSSION

The LOVD-China database, which was first built by Zhejiang University as part of the International Human Variome Project, has properly managed and stored thousands of phenotype-genotype datasets from China in strict accordance with the regulation of
Ministry of Science and Technology of PR China, since 2008 (Burn & Watson, 2016). The LOVD-China database has already embodied comprehensive mutation spectra and the phenotypic impact of several diseases, including breast cancer, colorectal cancer, and LQTS (Pan et al., 2011; Zhang et al., 2010). In this study, we established the LOVD-China database for hemoglobinopathies by integrating all the collectible variants corresponding to the candidate genes focusing on a Chinese population, especially 74 functional modifier variants identified from our local 2,087 hemoglobinopathies samples which will make efforts to provide a new target for precise diagnosis of the clinical severity β-thalassemia. In addition, we developed and validated a DASH aimed to help facilitate the accurate diagnosis and counseling from the results of both traditional approaches and molecular screening of hemoglobinopathies in Chinese. Six globin genes (HBB, HBA1, HBA2, HB D, HBG1, and HBG2) and three nonglobin modifiers (KLF1, BCL11A, and HMIP) have been shown to possess the greatest efficacy to statistically explain the modest clinical symptoms of β-thalassemia, while the contributions towards clinical severity have shown great ethnic-specificity. The reawakening of fetal hemoglobin based on these variants holds promise for new therapies for β-thalassemias (Bauer, Kamran, & Orkin, 2012). Our group has accumulated various kinds of samples representing different combinations of disease-causing variants and modifiers. For example, the KLF1 gene plays an important role in alleviating the clinical severity of β-thalassemia (D. Liu et al., 2014; Tepakhan et al., 2016). As the cases in Table 3 show, patients with the β0/β0 genotype, which may result in thalassemia major, turns out to be thalassemia intermediate when they carry functional variants in KLF1. Also, alpha multi-copies are considered to be modifier variants. The heterozygote of β-thalassemia is asymptomatic, whereas the heterozygote of β-thalassemia, combined with alpha multi-copies, results in a thalassemia intermediate phenotype (Mettananda, Gibbons, & Higgs, 2015; Table 3 and Table S3). Thus, the combined analysis module of DASH is necessary, especially for the accurate clinical genotyping of these samples.

There is an all-time difficulty to make an accurate determination of the morbidity for hemoglobinopathies mainly due to complicated environmental factors, medical conditions, and individual difference. Besides, as mentioned before, modifier genes have a significant impact on the severity of hemoglobinopathies. Combination analysis of disease-causing and modifier variants is considered to be the key factor underlying accurate clinical genotyping (Danjou et al., 2015). During the era of next-generation sequencing, the bulk of variants and polymorphisms have been identified in the hemoglobinopathy-relevant genes, especially in modifier genes, such as the KLF1, BCL11A, and HMIP regions (Basak & Sankaran, 2016; Orkin, 2016). More and more variants in these genes were shown to be clinically effective, while the contributions towards clinical severity have shown great ethnic-specificity. The reawakening of fetal hemoglobin based on these variants holds promise for new therapies for β-hemoglobinopathies (Bauer, Kamran, & Orkin, 2012). Our group has accumulated various kinds of samples representing different combinations of disease-causing variants and modifiers. For example, the KLF1 gene plays an important role in alleviating the clinical severity of β-thalassemia (D. Liu et al., 2014; Tepakhan et al., 2016). As the cases in Table 3 show, patients with the β0/β0 genotype, which may result in thalassemia major, turns out to be thalassemia intermediate when they carry functional variants in KLF1. Also, alpha multi-copies are considered to be modifier variants. The heterozygote of β-thalassemia is asymptomatic, whereas the heterozygote of β-thalassemia, combined with alpha multi-copies, results in a thalassemia intermediate phenotype (Mettananda, Gibbons, & Higgs, 2015; Table 3 and Table S3). Thus, the combined analysis module of DASH is necessary, especially for the accurate clinical genotyping of these samples.

Molecular screening is an important method for identifying carriers so that we are able to offer counseling and prenatal diagnosis to reduce the birth rate of hemoglobin disorders. There are three groups of variants we considered to be included in the at-risk assessment for molecular
their assistance in establishing DASH system and routing maintenance; Yi Cheng, Dejian Pang, Zongrui Shen, Jin Huang and Mingli Xu et al. for data input for the database. This study was supported by research funding from National Key Research and Development program of China (2018YFA0507803 to Prof. Xu), National Key Research and Development program of China (2017YFC1001800 to Dr. Shang), National Natural Science Foundation of China (NSFC 31671314 to Prof. Xu), Science and Technology Program of Guangzhou (201604020045 to Prof. Xu), National Natural Science Foundation of China (NSFC 81870148 to Dr. Shang) and Natural Science Foundation of Guangdong Province (2017A030313673 to Dr. Shang).

CONFLICT OF INTEREST

The authors declare that there are no conflict of interest.

ORCID

Li Zhang http://orcid.org/0000-0002-7079-8308

REFERENCES

Basak, A., & Sankaran, V. G. (2016). Regulation of the fetal hemoglobin silencing factor BCL11A. Annals of the New York Academy of Sciences, 1368(1), 25–30. https://doi.org/10.1111/nyas.13024

Bauer, D. E., Kamran, S. C., & Orkin, S. H. (2012). Reawakening fetal hemoglobin: Prospects for new therapies for the β−thal globin disorders. Blood, 120(15), 2945–2953. https://doi.org/10.1182/blood-2012-06-292078

Bauer, D. E., & Orkin, S. H. (2015). Hemoglobin switching's surprise: The versatile transcription factor BCL11A is a master repressor of fetal hemoglobin. Current Opinion in Genetics & Development, 33, 62–70. https://doi.org/10.1016/j.gde.2015.08.001

Burn, John, & Watson, Michael (2016). The human virome project. Human Mutation, 37(6), 505–507. https://doi.org/10.1002/humu.22986

Cao, A., & Kan, Y. W. (2013). The prevention of thalassemia. Cold Spring Harbor Perspectives in Medicine, 3(2), a011775. https://doi.org/10.1101/cshperspect.a011775

Danjou, F., Francavilla, M., Anni, F., Satta, S., Demartis, F. R., Perseu, L., & Galanello, R. (2015). A genetic score for the prediction of beta-thalassemia severity. Haematologica, 100(4), 452–457. https://doi.org/10.3324/haematol.2014.113886

den Dunnen, J. T., Dalgleish, R., Maglott, D. R., Hart, R. K., Greenblatt, M. S., McGowan-Jordan, J., & Taschner, P. E. (2016). HGVS Recommendations for the description of sequence variants: 2016 Update. Human Mutation, 37(6), 564–569. https://doi.org/10.1002/humu.22981

Giardine, B., Borg, J., Higgs, D. R., Peterson, K. R., Philippsen, S., Maglott, D., & Patrinos, G. P. (2011). Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nature Genetics, 43(4), 295–301. https://doi.org/10.1038/ng.785

Giardine, B., Borg, J., Viennes, E., Pavlidis, C., Moradkhani, K., Joly, P., & Patrinos, G. P. (2014). Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Research, 42(Database issue), D1063–D1069. https://doi.org/10.1093/nar/gkt911

Hallam, S., Nelson, H., Gregor, V., Perreault-Micale, C., Davie, J., Faulkner, N., & Kennedy, C. J. (2014). Validation for clinical use of, and initial clinical experience with, a novel approach to population-based carrier screening using high-throughput, next-generation DNA sequencing. Journal of Molecular Diagnostics, 16(2), 180–189. https://doi.org/10.1016/j.jmoldx.2013.10.006

TABLE 3 26 complicated cases of compound heterozygotes in combination with modifier variants

| Major classes                  | Genotypes                              | Number of patients | TM | Ti |
|--------------------------------|----------------------------------------|--------------------|----|----|
| β-thal modification samples    | (β0/β0, ααα/ααα)                        | 4                  | 19 |    |
| α-Globin gene triplexation     | (β0/β0, ααα/ααα)                        | 3                  | 0  |    |
| Other modifier variants        | (β0/β0, ααα/ααα)                        | 1                  | 0  |    |
| Atypical thalassemia samples   | (β0/β0, ααα/ααα)                        | 0                  | 5  |    |
| Microcytic hypochromic anemia  | (β0/β0, ααα/ααα)                        | 0                  | 3  |    |

Note: Four significant variants*: 4 functional variants exerting a significant impact on the clinical severity of β-thalassemia patients: HBA1 and HBA2 disease-causing variants, rs7482144 (Kmn1), rs61749494 (BCL11A), and rs1779553 (HMIP). Details of all 26 samples are available in the Supporting Information document (Table S3). The bold values means the number of TM(thalassemia major) or Ti(thalassemia intermedia) patients, with no special significance.

Abbreviations: Ti, thalassemia intermedia; TM, thalassemia major.
Compound heterozygosity for KLF1 mutations is associated with microcytic hypochromic anemia and increased fetal hemoglobin. European Journal of Human Genetics, 23(10), 1341–1348. https://doi.org/10.1038/ejhg.2014.291

Kountouris, P., Lederer, C. W., Fanis, P., Feleki, X., Old, J., & Kleanthous, M. (2014). IthaGenes: An interactive database for haemoglobin variations and epidemiology. PLOS One, 9(7), e103020. https://doi.org/10.1371/journal.pone.0103020.

Liu, D., Zhang, X., Yu, L., Ma, X., Zheng, C., & Xu, X. (2014). KLF1 mutations are relatively more common in a thalassemia endemic region and ameliorate the severity of β-thalassemia. Blood, 124(5), 803–811. https://doi.org/10.1182/blood-2014-03-561779.

Liu, H., Huang, K., Liu, S., Sun, H., Lin, K., Huang, X., & Yang, Z. (2016). Gene frequencies and haplotype distribution of hemoglobin E among seven minority groups of Yunnan, China. American Journal of Human Biology, 28(6), 927–931. https://doi.org/10.1002/ajhb.22868.

Mettananda, S., Gibbons, R. J., & Higgs, D. R. (2015). α-Globin as a molecular target in the treatment of β-thalassemia. Blood, 125(24), 3694–3701. https://doi.org/10.1182/blood-2015-03-633594.

Orkin, S. H. (2016). Recent advances in globin research using genome-wide association studies and gene editing. Annals of the New York Academy of Sciences, 1368(1), 5–10. https://doi.org/10.1111/nyas.13001.

Pan, M., Cong, P., Wang, Y., Lin, C., Yuan, Y., Dong, J., & Qi, M. (2011). Novel LOVD Databases for hereditary breast cancer and colorectal cancer genes in the Chinese population. Human Mutation, 32(12), 1335–1340. https://doi.org/10.1002/humu.21588.

Panja, A., Chowdhury, P., & Basu, A. (2016). Hb Midnapore [αS3(2D4) Ala→Val; HBB.C161C→T]: A Novel Hemoglobin Variant with a Structural Abnormality Associated with IVS-I-5 (G>C) (HBB: C.92+5G>C) Found in a Bengali Indian Family. Hemoglobin, 40(5), 300–303. https://doi.org/10.1080/03630269.2016.1243555.

Perkins, A., Xu, X., Higgs, D. R., Patrinos, G. P., Arnaud, L., & Bleker, J. J., KLF1 Consensus Workgroup. (2016). Krüppel–erythroptosis: An unexpected broad spectrum of human red blood cell disorders due to KLF1 variants. Blood, 127(15), 1856–1862. https://doi.org/10.1182/blood-2016-01-694331.

Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., & Gastier-Foster, J., ACMG Laboratory Quality Assurance Committee. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine, 17(5), 405–424. https://doi.org/10.1038/gim.2015.30.

Shang, X., Peng, Z., Ye, Y., Asan, Zhang, X., Chen, Y., & Xu, X. (2017). Rapid targeted next-generation sequencing platform for molecular screening and clinical genotyping in subjects with hemoglobinopathies. EBioMedicine, 23(2017), 150–159. https://doi.org/10.1016/j.ebiom.2017.08.015.

Taher, A. T., Weatherall, D. J., & Cappellini, M. D. (2018). Thalassaemia. Lancet, 391(10116), 155–167. https://doi.org/10.1016/S0140-6736(17)31822-6.

Tepakhan, W., Yamrsi, S., Sanchaisuriya, K., Fucharoen, G., Xu, X., & Fucharoen, S. (2016). Nine known and five novel mutations in the erythroid transcription factor KLF1 gene and phenotypic expression of fetal hemoglobin in hemoglobin E disorder. Blood Cells, Molecules, and Diseases, 59, 85–91. https://doi.org/10.1016/j.bcmd.2016.04.010.

Vinjamur, D. S., Bauer, D. E., & Orkin, S. H. (2017). Recent progress in understanding and manipulating hemoglobin switching for the haemoglobinopathies. European Journal of Human Genetics, 23(4), 560. https://doi.org/10.1038/ejhg.2015.39.

Ware, R. E., de Montalembert, M., Tshilolo, L., & Abboud, M. R. (2017). Sickle cell disease. Lancet, 390(10091), 311–323. https://doi.org/10.1016/S0140-6736(17)30193-9.

Weatherall, D. J. (2010). The inherited diseases of hemoglobin are an emerging global health burden. Blood, 115(22), 4331–4336. https://doi.org/10.1182/blood-2010-01-251348.

Xiong, F., Sun, M., Zhang, X., Cai, R., Zhou, Y., Lou, J., & Xu, X. (2010). Molecular epidemiological survey of haemoglobinopathies in the Guangxi Zhuang Autonomous Region of Southern China. Clinical Genetics, 2, 139–148. https://doi.org/10.1111/j.1399-0004.2010.01430.x.

Zhang, T., Moss, A., Cong, P., Pan, M., Chang, B., Zheng, L., & Qi, M. (2010). LOVD gene LOVD database. Human Mutation, 31(11), E1801–E1810. https://doi.org/10.1002/humu.21341.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Zhang L, Zhang Q, Tang Y, et al. LOVD-DASH: A Comprehensive LOVD database coupled with diagnosis and an at–risk assessment system for hemoglobinopathies. Human Mutation. 2019;40:2221–2229. https://doi.org/10.1002/humu.23863